Practice Management News

The Canadian Association for the Study of the Liver, or CASL, released a guideline today that now recommends screening patients born between 1945 and 1975 for hepatitis C virus.

WASHINGTON – Many women in medicine, despite their high performance and success, have a pervasive feeling that they are professionally successful because of hard work and chance, not because they are intelligent. Further, they tend to externalize all their successes instead of internalize them, said the chief of gastroenterology and hepatology at the Henry Ford Hospital, here at Digestive Disease Week 2018.

WASHINGTON, D.C. — Over the next four days, the gastroenterology community will convene in the nation’s capital for Digestive Disease Week 2018, the specialty’s largest scientific conference.

The majority of patients receiving opioid analgesics used immediate-release formulations, regardless of the duration of use, according to findings recently published in JAMA Network Open.

The rates of infections after endoscopic procedures performed at ambulatory surgical centers in the U.S. are far higher than previously thought, according to Johns Hopkins researchers.

The FDA released several draft guidances today that it said it hopes will assist generic drug makers get their products through the development and approval process while keeping the agency’s Risk Evaluation and Mitigation Strategy, or REMS, safety controls in place.

A new report issued by the AMA revealed that opioid prescribing has decreased nationwide, while the use of state prescription drug monitoring programs, access to naloxone and the number of physicians trained to treat opioid use disorder have all increased, according to a press release.

Hurricane season starts June 1, for many bringing memories of the severe storms that battered the United States in 2017 and serving as a reminder of the importance of preparedness.

On May 30, President Donald J. Trump signed “right to try” legislation, which allows terminally ill patients to seek investigational drugs that have passed the first phase of FDA approval but have not received final approval, into law.

The NIH was the single largest financial contributor to the systematic reviews that led to the U.S. Preventive Services Task Force recommendations, according to data recently published in JAMA.